Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports corporate governance changes effective January 6, 2017. The report was filed on January 3, 2017, covering events occurring on December 29 and 30, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensatory arrangements.
Material Changes
- Departure: David-Alexandre C. Gros, M.D., resigned as Senior Vice President, Chief Business Officer, and Principal Financial Officer (CFO) effective January 6, 2017, citing personal interest in returning to the West Coast.
- Appointment: Michael P. Mason was appointed as the new Principal Financial Officer, effective January 6, 2017. Mr. Mason previously held this role from February 2011 to June 2016 and currently serves as Vice President, Finance, Treasurer, and Principal Accounting Officer.
Guidance, Outlook, and Compensatory Arrangements
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It details a compensatory arrangement for the new CFO:
- On December 30, 2016, Michael P. Mason was granted 8,502 restricted stock units (RSUs) under the Company's 2009 Stock Incentive Plan.
- The RSUs vest in full on December 30, 2017, contingent upon Mr. Mason remaining an eligible participant.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (January 6, 2017).
- Verify the vesting schedule and conditions for the 8,502 RSUs granted to Michael P. Mason.
- Review subsequent filings for the appointment of a replacement for the Chief Business Officer role, which was vacated by Dr. Gros.